ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: For example, ABL1 inhibition in chronic myeloid leukemia (CML), characterized by clonal BCR–ABL1 fusions, has revolutionized therapy for this disease, yet the development of resistance remains a challenge in a proportion of patients.